Northwell Health’s science arm Feinstein Institutes for Medical Research in the US has commenced the clinical trial of a third dose of Moderna’s Covid-19 vaccine in individuals living with an organ transplant.

Sponsored by Moderna, the multicentre, nationwide trial will assess the efficacy of a third shot administered following the initial two-dose regimen in patients in the country.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Individuals who have had an organ transplant are at an increased risk of contracting Covid-19 and developing severe disease.

Immunosuppressive treatments used after an organ transplant could hinder the recipient’s ability to develop a robust immune defence against SARS-CoV-2 by administering a two-dose vaccine regimen, Feinstein noted.

The trial intends to enrol 240 subjects, including healthy participants, with the Feinstein Institutes being one of the seven trial centres leading the study.

It will analyse the immune antibody response of the transplant patients 28 days from the third dose.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Feinstein Institutes clinical research vice-president Christina Brennan said: “Since the start of the Covid-19 pandemic, the Feinstein Institutes focused on conducting clinical trials in an effort to find safe and effective treatments.

“Now, with the support of Moderna, we hope this vaccine clinical trial will give insight into the best way to protect a high-risk population.”

In March 2020, the Feinstein Institutes launched its initial set of trials to analyse the safety and efficacy of potential Covid-19 treatments.

The institute commenced subject enrolment in another trial in the US to test the antibody response on receiving booster shots of authorised or approved vaccines in patients with an autoimmune disease.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact